drug · small molecule

BIMATOPROST

Phase 2updated 2mo ago

by $AMRX Amneal Pharmaceuticals, Inc.🔗 ChEMBL

Phase 2

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 8 investigational indications.

targets

Prostaglandin F2-alpha receptor

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

BIMATOPROST

trade names

Bimatoprost, Bimatoprost component of ganfort, Durysta, Latisse, Lumigan

generic

BIMATOPROST

MOA

12.1 Mechanism of Action Bimatoprost, a prostaglandin analog, is a synthetic structural analog of prostaglandin with ocular hypotensive activity. It selectively mimics the effects of naturally occurring substances, prostamides. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Elevated IOP presents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.

indication

1 INDICATIONS AND USAGE Bimatoprost ophthalmic solution 0.03% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. Bimatoprost ophthalmic solution 0.03% is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. ( 1 )

phase

phase_2

BIMATOPROST

targets

all catalysts(0)

News(0)

comments(0)

Report a data issue

🐶 often sniffed alongside

Trials studying BIMATOPROST